FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 129 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in... November 16, 2022 Should alcohol marketing be dropped from televised sport? August 27, 2021 Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says June 2, 2020 FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... February 6, 2025 Load more HOT NEWS Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About... FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma Shannen Doherty Opens Up About Life After Cancer And BH90210 Breast-Cancer Mom Is Living On 84 Pence As She Fights For...
